Taking law firm business intelligence to the next level

Linda D. Garrow

Original article can be found here – https://www.theaccessgroup.com/en-gb/blog/lgl-taking-law-firm-business-intelligence-to-the-next-level/ This blog explores how law firms can take business intelligence to the next level and why it’s important to do so. It recognises the age-old principle that the legal profession has been built upon: ‘making data pay’. Of course, the way we […]

How I Made It to Law Firm Leadership: ‘When Opportunities Arose, I Said Yes,’ Says Alison Ashmore of Dykema Gossett

Linda D. Garrow

Job Title: Member; executive board member. Practice Area: Business Litigation Practice Group. Law school and year of graduation: Baylor Law School, 2007. How long have you been at the firm? Nine years, since February 2013. Alison Ashmore/courtesy photo How long were you a partner at the firm before being promoted to firm leadership? I […]

Law Firm Career | Law Student Career Journey

Linda D. Garrow

Why have you chosen to make your career at Husch Blackwell? I chose Husch Blackwell because of its commitment to diversity, equity & inclusion (DE&I). Through the firm’s DE&I leadership, inclusion is discussed and pushed forward on all levels – the entire depth of what inclusion means, not merely the […]

Kessler Topaz Meltzer & Check, LLP Reminds Investors of C3.ai, Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm

Linda D. Garrow

RADNOR, Pa., April 22, 2022 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against C3.ai, Inc. (“C3”) (NYSE: AI). The action charges C3 with violations of the federal securities laws, including omissions and fraudulent misrepresentations […]

ROSEN, A LEADING LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors With Losses to Inquire About Securities Class Action Investigation – AUPH

Linda D. Garrow

Relatlimab is the third immune checkpoint inhibitor from Bristol Myers Squibb, adding to the Company’s growing and differentiated oncology portfolio Bristol Myers Squibb (NYSE: BMY) today announced that Opdualag TM (nivolumab and relatlimab-rmbw), a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion, was approved […]

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Linda D. Garrow

Relatlimab is the third immune checkpoint inhibitor from Bristol Myers Squibb, adding to the Company’s growing and differentiated oncology portfolio Bristol Myers Squibb (NYSE: BMY) today announced that Opdualag TM (nivolumab and relatlimab-rmbw), a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion, was approved […]